Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and other diseases, has an upcoming data readout that you should watch out for.
The company's lead drug candidate is Lanifibranor, the only pan-PPAR (peroxisome proliferator-activated receptor) agonist in clinical development for Non-alcoholic steatohepatitis (NASH).
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.